A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

NCT05941936 ↗

Phase 0 Unknown 5 enrolled Suzhou BlueHorse Therapeutics Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and IL-2 therapy.

Timeline

Start: 2023-05-19
Primary completion: 2025-02
Completion: 2026-02

Publications

Li F, Xu Y, Wang Y, Mu N, Liu M, Feng W, Xue Y, Wu S, Wang X, Lizee G, Ma C. Multiple autologous tumor-infiltrating lymphocyte (LM103 infusion) therapy combined with immune checkpoint inhibitor induces repeated tumor regression in a patient with aggressive mucosal melanoma: a case report and literature review. Front Oncol. 2026 Apr 23;16:1789442. doi: 10.3389/fonc.2026.1789442. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LM103	Cell therapy	5e+09 cells	Intravenous

Indications

No indication recorded.